Compare
Butterfly Network, Inc. vs Biolife Solutions Inc vs NeuroPace Inc vs Kestra Medical Technologies, Ltd.
| Latest fiscal year | Butterfly Network, Inc. BFLY | Biolife Solutions Inc BLFS | NeuroPace Inc NPCE | Kestra Medical Technologies, Ltd. KMTS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-04-30 |
| Revenue | $97.61M | $96.21M | $99.99M | $95.13M |
| Revenue growth (YoY) | +19.0% | +28.9% | +25.1% | +59.0% |
| Gross margin | 46.9% | 64.6% | 77.2% | 51.4% |
| Operating margin | -88.5% | -17.3% | -16.3% | -141.6% |
| Net margin | -79.0% | -4.8% | -21.5% | -138.4% |
| Net income | -$77.06M | -$4.59M | -$21.46M | -$131.61M |
| EPS (Diluted) | -$0.31 | -$0.10 | -$0.66 | -$2.43 |
| Operating cash flow | -$12.70M | $20.11M | -$11.01M | -$81.70M |
| Free cash flow | -$16.05M | $10.64M | -$11.34M | -$116.59M |
| Cash & equivalents | $150.49M | $33.04M | $21.69M | $99.71M |
| Total assets | $296.53M | $405.88M | $105.56M | $358.46M |
| Total liabilities | $100.55M | $34.00M | $86.53M | $98.81M |
| Shareholders' equity | $195.98M | $371.89M | $19.03M | $259.66M |
| Return on year-end equity | -39.3% | -1.2% | -112.8% | -50.7% |
| Shares outstanding | n/a | 48.20M | 33.57M | 58.38M |
Revenue, most recent five fiscal years
| Fiscal year | Butterfly Network, Inc. | Biolife Solutions Inc | NeuroPace Inc | Kestra Medical Technologies, Ltd. |
|---|---|---|---|---|
| Latest | $97.61M Ended 2025-12-31 | $96.21M Ended 2025-12-31 | $99.99M Ended 2025-12-31 | $95.13M Ended 2026-04-30 |
| 1 year earlier | $82.06M Ended 2024-12-31 | $74.65M Ended 2024-12-31 | $79.91M Ended 2024-12-31 | $59.81M Ended 2025-04-30 |
| 2 years earlier | $65.90M Ended 2023-12-31 | $68.02M Ended 2023-12-31 | $65.42M Ended 2023-12-31 | $27.81M Ended 2024-04-30 |
| 3 years earlier | $73.39M Ended 2022-12-31 | $76.24M Ended 2022-12-31 | $45.52M Ended 2022-12-31 | n/a |
| 4 years earlier | $62.56M Ended 2021-12-31 | $119.16M Ended 2021-12-31 | $45.18M Ended 2021-12-31 | n/a |